Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJun 30, 2026
DataAggregated Company Financials
Companies20
  • 7D4.2%
  • 3M26.9%
  • 1Y-24.3%
  • YTD-7.1%

Over the last 7 days, the Healthcare industry has risen 4.2%, driven by gains from Novo Nordisk of 5.0%. In contrast, the industry has lost 24% in the last 12 months. Looking forward, earnings are forecast to grow by 1.7% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 01 Jul 2026DKK 1.8tDKK 469.2bDKK 147.1b19.9x12.3x3.9x
Fri, 29 May 2026DKK 1.7tDKK 468.6bDKK 147.0b20.4x11.7x3.7x
Sun, 26 Apr 2026DKK 1.6tDKK 447.3bDKK 129.9b18.3x12x3.5x
Tue, 24 Mar 2026DKK 1.4tDKK 447.5bDKK 130.0b16.4x11.1x3.2x
Thu, 19 Feb 2026DKK 1.8tDKK 447.4bDKK 131.0b18.5x13.9x4.1x
Sat, 17 Jan 2026DKK 2.2tDKK 454.1bDKK 137.0b18.6x16.4x4.9x
Mon, 15 Dec 2025DKK 1.9tDKK 453.8bDKK 136.9b17.4x14.1x4.2x
Wed, 12 Nov 2025DKK 1.9tDKK 452.9bDKK 135.7b18.2x13.9x4.2x
Fri, 10 Oct 2025DKK 2.2tDKK 447.8bDKK 141.8b18.4x15.5x4.9x
Sun, 07 Sep 2025DKK 2.0tDKK 447.3bDKK 141.7b19.9x14.5x4.6x
Tue, 05 Aug 2025DKK 1.8tDKK 423.5bDKK 124.6b29.3x14.7x4.3x
Thu, 03 Jul 2025DKK 2.4tDKK 422.9bDKK 124.4b30.8x19.4x5.7x
Sat, 31 May 2025DKK 2.5tDKK 423.9bDKK 124.7b30.4x19.9x5.8x
Mon, 28 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b21.9x18.6x5.5x
Wed, 26 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.4x22.8x6.7x
Fri, 21 Feb 2025DKK 3.2tDKK 410.0bDKK 121.4b27.5x26.3x7.8x
Sun, 19 Jan 2025DKK 3.1tDKK 387.5bDKK 111.3b28.5x27.9x8x
Tue, 17 Dec 2024DKK 4.0tDKK 387.4bDKK 111.3b30.3x35.8x10.3x
Thu, 14 Nov 2024DKK 3.9tDKK 386.3bDKK 110.7b31.9x35.4x10.1x
Sat, 12 Oct 2024DKK 4.2tDKK 372.0bDKK 107.1b37x39.3x11.3x
Mon, 09 Sep 2024DKK 4.5tDKK 371.9bDKK 107.2b34.9x42.2x12.2x
Wed, 07 Aug 2024DKK 4.5tDKK 355.3bDKK 106.3b35.9x42.6x12.7x
Fri, 05 Jul 2024DKK 4.9tDKK 355.3bDKK 106.2b35.4x46x13.8x
Sun, 02 Jun 2024DKK 4.7tDKK 355.3bDKK 106.2b36.8x44.1x13.2x
Tue, 30 Apr 2024DKK 4.5tDKK 341.4bDKK 99.6b34.3x45.3x13.2x
Thu, 28 Mar 2024DKK 4.5tDKK 341.2bDKK 99.6b39.3x45.4x13.3x
Sat, 24 Feb 2024DKK 4.4tDKK 340.1bDKK 98.9b38.2x44.2x12.9x
Mon, 22 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b34.5x42.1x11.8x
Wed, 20 Dec 2023DKK 3.6tDKK 320.5bDKK 90.0b32.5x39.5x11.1x
Fri, 17 Nov 2023DKK 3.5tDKK 320.1bDKK 90.3b33.5x38.8x11x
Sun, 15 Oct 2023DKK 3.7tDKK 305.5bDKK 82.2b30.7x45x12.1x
Tue, 12 Sep 2023DKK 3.6tDKK 305.4bDKK 82.2b35.7x43.6x11.7x
Thu, 10 Aug 2023DKK 3.4tDKK 288.2bDKK 74.9b40.4x44.8x11.6x
Sat, 08 Jul 2023DKK 2.9tDKK 287.0bDKK 75.5b39.4x38.9x10.2x
Price to Earnings Ratio

38.9x


Total Market Cap: DKK 2.9tTotal Earnings: DKK 75.5bTotal Revenue: DKK 287.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 29.3x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 12.3x which is lower than its 3-year average PE of 29.3x.
  • The 3-year average PS ratio of 8.5x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 25% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market1.42%
Healthcare4.19%
Healthcare Services14.81%
Pharma4.63%
Biotech3.15%
Medical Equipment1.76%
Life Sciences-1.78%
Healthtech-4.00%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry, which is trading close to its 3-year average PE ratio of 33.0x.
    • Analysts are expecting annual earnings growth of 20.0%, which is higher than its past year's earnings growth of 0.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 113% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 9.5% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 314.602.2%
+DKK 30.3b		-28.2%PE11.4x
GMAB GenmabDKK 1.80k5.1%
+DKK 5.3b		36.6%PE20.5x
DEMANT DemantDKK 268.204.8%
+DKK 2.6b		0.8%PE23.9x
BAVA Bavarian NordicDKK 182.703.6%
+DKK 481.9m		8.7%PE11.9x
EMBLA Embla Medical hfDKK 26.803.3%
+DKK 362.4m		-21.2%PE20.4x

Latest News

GMAB
DKK 1,795.00
Genmab
7D
5.1%
1Y
36.6%
BAVA
DKK 182.70
Bavarian Nordic
7D
3.6%
1Y
8.7%
NOVO B
DKK 314.60
Novo Nordisk
7D
2.2%
1Y
-28.2%
Narrative Update • Jun 29

NOVO B: Higher P E Multiple Will Expose Cybersecurity And Margin Execution Risks

Novo Nordisk’s updated analyst price target has moved from DKK 186.48 to DKK 200.00, with analysts citing refined assumptions around slightly slower revenue declines, a modestly lower profit margin, and a higher future P/E multiple as key drivers of the change. Analyst Commentary For Novo Nordisk, the move to a DKK 200.00 price target reflects a more measured stance from analysts, who are fine tuning their expectations around revenue resilience, profitability, and the valuation investors may be willing to pay through the cycle.
ALK B
DKK 244.20
ALK-Abelló
7D
-4.9%
1Y
30.0%
Narrative Update • Jun 26

ALK B: Paediatric Allergy Approvals Will Drive Future Immunotherapy Leadership

Analysts have raised their price target on ALK-Abelló from DKK 243 to DKK 305, citing the company's position as a global leader in allergy immunotherapy as a key factor in their updated view. What’s in the News for ALK-Abelló UK regulator MHRA granted marketing authorisation for EURneffy 1 mg, the first needle free adrenaline treatment for anaphylaxis in children aged 4 and older weighing 15 to less than 30 kg, expanding ALK-Abelló’s emergency allergy treatment options in the UK.
ZEAL
DKK 289.60
Zealand Pharma
7D
1.3%
1Y
-20.6%
Narrative Update • Jun 25

ZEAL: Obesity Pipeline Progress And Buybacks Will Support Future Re Rating

Zealand Pharma's analyst price target has moved from about DKK 825 to roughly DKK 300, as analysts point to a longer timeline to unlock upside, lower peak sales expectations for key pipeline drugs, and revised assumptions that include a higher future P/E multiple and softer projected growth and margins. Analyst Commentary Recent Street research on Zealand Pharma highlights a mix of caution and optimism, with several analysts revisiting their assumptions on valuation, execution timelines, and the growth potential of key pipeline assets such as petrelintide and survodutide.
EMBLA
DKK 26.80
Embla Medical hf
7D
3.3%
1Y
-21.2%
Narrative Update • Jun 24

EMBLA: Recent Buybacks Will Support Future Upside Potential

Analysts have kept their DKK price target for Embla Medical hf broadly steady, with only a marginal adjustment that reflects small tweaks to assumptions around the discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Embla Medical hf reported completion of a share repurchase program covering 556,103 shares, equivalent to 0.13% of the company, for a total consideration of $2.6 million.
HLUN B
DKK 42.48
H. Lundbeck
7D
-1.5%
1Y
15.4%
GUBRA
DKK 321.80
Gubra
7D
-3.1%
1Y
-28.1%
Narrative Update • Jun 24

GUBRA: Upcoming Phase 2 Obesity Milestone Will Support Long Term Upside

Analysts have kept their DKK 451.50 price target for Gubra unchanged, citing only minor tweaks to the discount rate and future P/E assumptions, without a shift in their overall valuation view. What's in the News for Gubra Gubra highlighted that partner Boehringer Ingelheim plans to start Phase 2 clinical development in mid 2026 for BI 3034701, a potential first in class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity and related metabolic diseases, based on Gubra discovered technology.
DEMANT
DKK 268.20
Demant
7D
4.8%
1Y
0.8%
Narrative Update • Jun 23

DEMANT: Fair Value View Balances Growth Inflection Hopes With Execution Risks

Analysts have lifted their price expectations for Demant, with the consensus fair value estimate moving from DKK 240.32 to DKK 251.11. Recent research points to a higher price target range supported by updated views on growth, profitability and future P/E multiples.
AMBU B
DKK 61.00
Ambu
7D
-2.6%
1Y
-38.2%
Narrative Update • Jun 17

AMBU B: Bearish Downgrade And Stable Assumptions May Support Future Repricing

Analysts have reduced their price target on Ambu shares to DKK 88.8, citing a more cautious stance reflected in recent research, including a downgrade from Danske Bank. This comes even as underlying model inputs such as the discount rate, growth and future P/E assumptions remain broadly unchanged.
COLO B
DKK 372.30
Coloplast
7D
-0.9%
1Y
-37.9%
Narrative Update • Jun 16

COLO B: Recent Pullback And New FDA Approval Will Support Future Re Rating

The analyst price target for Coloplast has been revised slightly, with the updated fair value held around DKK 462 as analysts factor in a modestly lower discount rate and only small tweaks to growth and margin assumptions following a series of recent target cuts and one new Buy initiation around DKK 482. Analyst Commentary Recent research on Coloplast highlights a split in opinion, with some analysts seeing value after the share price pullback and others focusing on execution risk and margin pressure in their updated targets.
MONSO
DKK 0.36
Monsenso
7D
-26.4%
1Y
7.9%
SMSMED
DKK 3.20
Scandinavian Medical Solutions
7D
11.9%
1Y
-30.4%
BIOPOR
DKK 1.08
BioPorto
7D
-4.0%
1Y
-22.6%
NNIT
DKK 39.05
NNIT
7D
2.2%
1Y
-42.1%
CHEMM
DKK 362.20
ChemoMetec
7D
-2.4%
1Y
-35.6%